CpG methylation profiling in lung cancer cell lines, tumors and non-tumors 

Mapping 3D genome structures: a data driven modeling method for integrated structural analysis 

The role of Hic-5 in glucocorticoid receptor binding to chromatin 

Polygenes and estimated heritability of prostate cancer in an African American sample using genome-wide association study data 

DNA methylation changes in the development of lung adenocarcinoma 

Effects of chromatin regulators during carcinogenesis 

Genomic and transcriptomic alterations of apolipoproteins genes in cancers 

TLR8-transferred miR-192 acts as a tumor suppressor in neuroblastoma by inhibiting CTCF 

Investigating the function of dysregulated HOX genes in prostate cancer 

Study of the role of bone morphogenetic proteins in prostate cancer progression 

Using chemical biology approaches to investigate the consequences of protein concentration and activity in cancer cells 

A population genomics approach to the study of speciation in flowering columbines 

Ectopic expression of a truncated isoform of hair keratin 81 in breast cancer alters biophysical characteristics to promote metastatic propensity 

Genome-scale modeling of macrophage activity in the colorectal cancer microenvironment 

Studies of murine prostate cancer stem / progenitor cells 

The role of endoplasmic reticulum chaperone glucose-regulated 78-kilodalton (GRP78) in lung cancer 

Runx2 interactions with the osteoblast genome 

pRB structures and functions mediating suppression of retinoblastoma initiation 

Evaluating novel chemotherapeutic strategies in colorectal and gastric cancer: the role of histone deacetylase inhibitors and human epidermal receptor family inhibitors 

Whole genome bisulfite sequencing: analytical methods and biological insights 

UVRAG maintains genomic integrity 

Functional role of chromatin remodeler proteins in cancer biology 

Extending genome-wide association study methods in African American data 

Functional DNA methylation changes in normal and cancer cells 

The effect of tumor-mediated immune suppression on prostate cancer immunotherapy